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PEMBANGUNAN SENARAI SEMAK DRP YANG BERASASKAN BUKTI 
UNTUK MENGESAN MASALAH BERKAITAN DRUG (DRPS) DI 
KALANGAN PESAKIT DENGAN SIMPTOM ALAHAN DI FARMASI 
KOMUNITI 
 
ABSTRAK 
 
Amalan farmasi komuniti telah banyak membuat penambahbaikan dalam kualiti 
dan keselamatan pesakit terutamanya dalam mengesan ‘masalah yang berkaitan dengan 
drug (DRP)’ yang berkenaan dengan penjagaan farmaseutikal. Objektif kajian ini adalah 
untuk membangunkan satu senarai semak yang dapat mengesan masalah berkaitan 
dengan drug di kalangan pesakit dengan alahandi farmasi komuniti. Kajian ini juga 
bertujuan untuk mengesan jenis (DRP) dan kelazimannya di Seremban dalam konteks 
gejala alahan. Kajian ini dibahagikan kepada fasa pembangunan senarai semak DRP 
yang melibatkan kajian literatur. Fasa pegesahan senarai semak DRP disahkan 
melaluivalidasi, sensitiviti dan spesifisiti dengan bantuan dua doktor pakar dan dua ahli 
farmasi. Senarai semak yang disahkan kemudiannya diuji di fasa terakhir yang 
dibahagikan kepada dua kumpulan iaitu Kumpulan 1 (dengan senarai semak) dan 
Kumpulan 2 (tanpa senarai semak). Dalam fasa pengesahan senarai semak, 378 pesakit 
telah ditemuramah. Hampir tiga belas peratus (12.96%) daripada pesakit telah dikenal 
xvii 
 
pasti mengalami DRP. DRP yang utama dikenalpasti adalah penyakit yang tidak 
dirawat dan pesakit yang memerlukan terapi tambahan. Purata pengunaan jenis ubat 
seorang pesakit menunjukkan mean 4.0 ± 2.7. Validasi senarai semak DRP 
menunjukkan nilai sensitiviti sebanyak 77.37% dan nilai spesifisiti sebanyak 98.24%. 
Analisis univariasi dengan nilai (p<0.05) berkaitan dengan ubat terutamanya steroid 
antihistamin dan antibiotic. Regresi logistik mengenalpasti pesakit mengalami alahan 
setelah mengambil makanan atau ubatan.Analisis multivariasi mengenalpasti 
polifarmasi, kealpaan, interaksi makanan/ubat/masalah kesihatan dan cara penstoran 
ubat adalah punca utama masalah DRP. Dalam fasa terakhir, seramai104 pesakit 
(Kumpulan 1) dan seramai 92 pesakit (Kumpulan 2) telah ditemuramah. Kumpulan 1 
berjaya mengesan lebih bilangan pesakit dengan DRP berbanding Kumpulan 2.  
Kajian ini berjaya membangunkan satu senarai semak yang boleh digunakan sebagai 
kaedah pengesanan DRP di kalangan pesakit yang menerima rawatan di farmasi 
komuniti di kawasan Seremban.  
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DEVELOPMENT OF AN EVIDENCE-BASED CHECKLIST FOR THE 
DETECTION OF DRUG-RELATED PROBLEMS (DRPS) AMONG PATIENTS 
WITH ALLERGY SYMPTOMS IN COMMUNITY PHARMACIES 
 
        ABSTRACT 
 
Pharmacists in community practice is making many improvements in the quality and 
safety of patients especially in detecting drug related problems (DRP) related to 
pharmaceutical care. The objective of this study was to develop a checklist which would 
be able to detect drug related problems among patients with allergy symptoms who seek 
treatment in community pharmacies. This study also aimed to detect types of DRPs and 
its prevalence.The Checklist Development Phase involved review of literatures. The 
developed checklist was then tested in validation phase where it was used in a 
community setting to obtain data and to get it validated. Four expert panel agreement, 
predictive values, sensitivity and specificity tests were done to validate the checklist. 
This validated checklist was then field-tested in two groups (Group 1; with the 
checklist) and (Group 2; without checklist).During the validation phase, 378 patients 
were interviewed. About thirteen percent (12.96%) of them were identified as 
xix 
 
having DRPs. Main DRPs identified were untreated indication and in need of additional 
therapy. Average types of medication usage per patient weremean 4.0 ± 2.7. Validation 
of the checklist showed sensitivity of 77.37% and specificity of 98.24%. Univariate 
analysis with significant DRP value (p<0.05) were detected from the usage of 
medication such as steroids, antihistamines and antibiotics. Logistic regression 
identified significant DRPs among patients who had allergy symptoms after ingestion of 
food or medications. Whereas multivariate analysis identified polypharmacy, 
forgetfulness, food/medicine/medical history and improper storage of medicine as main 
causes of DRPs.During the field test, 104 patients were interviewed in Group1 whereas 
92 patients were interviewed in Group 2. Group 1 successfully identified more patients 
with DRPs compared to Group 2.The study managed to develop a checklist which can 
be used as a detection method for DRPs among patients who sought treatment in 
community pharmacies in Seremban. 
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CHAPTER 1 
1.0 INTRODUCTION 
1.1 BRIEF OVERVIEW OF DRUG RELATED PROBLEMS  
Pharmaceutical cares are processes of cooperation between a pharmacist, the patient and 
other healthcare professionals. This group diagnoses and designs, implements, and 
monitors a therapeutic plan with specific therapeutic outcomes for the patient. This care 
is  provided for the good and direct benefit of the patient and the pharmacist is 
responsible to the patient for the quality of that care provided (Hepler and Strand 
1990). These processes involve three major functions: 
a) Identifying potential and actual drug related problems. 
b) Resolving actual drug related problems. 
c) Preventing potential drug-related problems. 
Prevention and reduction of drug-related problem morbidity and mortality are accepted 
as a social responsibility by the pharmacist profession (Billups, 2000). 
1.2 DRUG-RELATED PROBLEM MORBIDITY AND MORTALITY 
Drugs which are (prescription medication, over-the-counter medication and herbal 
medications) are widely used in the ambulatory population to lower down morbidity 
and mortality frequencies and to improve quality of life; however, they can also cause 
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significant and important problems that result in costs to the health care system. Drug 
related problems are associated with problems at different stages in the medication use 
process which involves the prescribing phase, dispensing phase and monitoring phase 
(Billups, 2000). 
1.3 PREVENTABILITY OF DRUG-RELATED MORBIDITY AND  
MORTALITY 
Drug related problem morbidity or mortality happens due to some unrealized or 
unexpected reaction and very patient-specific reason.  Some of the drug related problem 
morbidities that result from medication mishaps are also not known and unpredictable 
(Ives, et al., 1984). For example,  many   prescribed regimen  have standardized dosage  
ranges, and  if a patient experiences a toxic reaction  while receiving  a high  dose  
which is much   higher  than   usual,   the patient may be  justified  that the  toxicity  
would have  been  avoided if monitored carefully.  
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Table 1.0 Findings of DRPs from literature review 
RESEARCHER FINDINGS 
Hoe(2007) USM Hospital found 70 admission cases; (63.6%) DRPs were 
the total reason of admission. 
Shargel (2002) Studies on DRP especially on compliance in asthma, diabetes, 
 hypertensive and geriatric patients from 1995- 2001 showed 
compliance increased with the help/guidance from pharmacist 
in hospital settings.  
Burnum(1990) 42 ADRs were identified in a group of 1000 patients. 23 of the 
ADRs were preventable and six avoidable reactions were the 
source from the pharmacy. 
Trunet(1986) Unnecessary admissions due to DRPs accounted for about 
61% for the 1980 admissions of patients from severe care to 
intensive care. 
 
Ives, et al. (1984) stated that much  of the DRPs are not due to the drug products 
themselves  but  in  the  manner of how  they  are  prescribed,  dispensed and  used  by 
the patients. The prevalence of drug related problems morbidities and their indications 
show that much of them are preventable, and preventing them may actually diminish 
total costs while improving excellence of care. McKenney and Wasserman (1988) 
support the statements above with their research which show that pharmaceutical 
4 
 
services can significantly decrease DRPs, the total expenditure of care and the length of 
hospitalization. 
1.4 DRUG RELATED PROBLEM – LOCAL SCENARIO 
Allergy symptoms are commonly treated among patients who visit community 
pharmacies in our country. These patients could be facing DRPs due to medication 
therapies given by various healthcare professionals. Very limited studies on drug related 
problems (DRP) s among patients with allergy symptoms have been done in community 
pharmacies in Malaysia setting. A full scope of studies of DRPs due to the three phases 
which are the prescribing phase, dispensing phase and patient phase in our community 
pharmacies do not exist in Malaysia (Elkalmi, 2011). A proper survey method has to be 
developed to get proper data of DRP occurrence in Malaysia. 
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1.5 CURRENT HEALTHCARE SYSTEM  
 
 
 
 
 
 
(Figure 1.0 – Medical and medication information communication between community 
pharmacies and other health centers) 
Malaysia’s healthcare system consists of public and private health sectors. The 
government funds the public healthcare system which is supported mainly from taxes 
on earned income.  The public healthcare system provides services to everyone through 
a network of tertiary care centers, general hospitals, district hospitals and health clinics 
(Elkalmi, 2011). The private health sector, are combination of private hospitals and 
general practice (GPs) clinics, community pharmacies and traditional healthcare 
practitioners (Ministry of Health, Malaysia, 2011). In the view of private sector, 
medication usage in the community setting such as prescription medicines dispensing 
follow a traditional ‘dispensing doctors’ system where their professional practice allows 
Government/private hospital 
 
Government/private clinic 
 
Community pharmacy 
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general practitioners dispense medications (Sing, 2001). Until today there are no proper 
guidelines of communication and referrals’ between government or private hospitals or 
clinics and community pharmacies. Community pharmacists are unable to detect DRP 
efficiently because they are not given a standard guide for DRP reporting (Sing, 2001).  
From literature reviews, each country has their own definition and scenario about 
DRPs and has developed instruments to identify them in the community pharmacy 
setting such as PIE-system and PCNE V5.1 (Paulino, et al., 2007;Van Mil, et al., 2001). 
So far a few studies have been done to categorize and identify these DRPs in 
community pharmacies setting in Malaysia (Chua, 2012; Neo, 2010; Elkalmi, 2011). All 
these studies concentrated on different DRP aspects such as ADR 
pharmacovigilences(Elkalmi, 2011) and information collaboration rates between GPs 
and community pharmacists among chronic illness patients (Chua, 2012). 
 A proper screening instrument and checklist as a guide for community pharmacist 
should be developed to help our community pharmacies. A checking system which 
consists of patients’ medication history and basic patient assessment must be created to 
help community pharmacist to work together with other health centers to curb existing 
DRPs in Malaysia. 
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1.6 HYPOTHESIS 
An adapted or created DRP classification system or checklist used among community 
pharmacies in Malaysia could be the stepping stone to detect drug related problems and 
its causes, for the benefit of a nationwide integrated health system. Thus, the hypothesis 
for this research is: 
Ho: Development of a checklist may not be able to help the pharmacists to identify 
DRPs in the community pharmacy settings. 
HI :Development of a checklist may be able to help the pharmacists to identify DRPs in 
the community pharmacy settings. 
1.7 OBJECTIVES 
1.7.1 GENERAL OBJECTIVE 
To develop an evidence-based DRP (drug related problems) checklist that can be 
used to review patients’ clinical condition and medication treatment to recognize DRPs 
among patients who complained of allergy symptoms who visit a community pharmacy 
for treatment. 
1.7.2 SPECIFIC OBJECTIVES 
a) To develop a checklist to detect DRP among patients who come for allergy 
symptoms treatment in a community pharmacy. 
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b) To estimate prevalence of DRPs among patients with allergy symptoms who visit 
a community pharmacy for treatment. 
c) To categorize and to determine the types and causes of DRPs identified.  
d) To determine the types of patients with allergy symptoms who were at risks for 
DRPs.  
e) To validate the DRP checklist; specificity and sensitivity of the checklist  
f) To find association between DRPs and their problems and causes. 
1.7.3 SIGNIFICANCE OF THE THESIS 
A DRP checklist developed according to the local problems could help pharmacists 
to detect DRPs among patients who visit community pharmacies. The DRPs detected 
could be used as a tool to provide additional information for healthcare providers such 
as physicians to deliver good pharmaceutical care. In this research, allergy was selected 
as one of the criteria as it is one of the common complaint or symptoms among walk in 
patients in community pharmacies (Strannegard, 2001).  
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CHAPTER 2 
2.0 LITERATURE REVIEW 
This chapter aims to provide a conceptual and theoretical understanding for the study. 
The theoretical framework to DRP detection for patient care were first introduced to 
community pharmacy practice by American scientists Hepler and Strand in 1990 under 
the concept of Pharmaceutical Care (Hepler and Strand 1990). This study is based on a 
framework done by Bob (2009) which was related to the development of a DRP 
checklist in a major disease, development of DRP checklist in community pharmacy 
setting (Williams, 2012) and the DRP detection methods among pharmaceutical care 
issues by Chua (2012).Thus, this study concentrates on the development of DRP 
checklist in a community pharmacy among selected patients with types of allergy 
symptoms. Few types of DRP classification systems and studies are also reviewed in 
this chapter (Table 2.2).  
2.1 THE EVOLUTION OF DRUG RELATED PROBLEM DEFINITION  
 Drug-related problem was initially defined as “an undesirable patient incident that 
involves drug treatment and that actually or potentially interferes with a required patient 
result” (Strand, et al., 1990). The definition often used as a synonym with an expression 
“drug-therapy problem” which is distinct as “any unwelcomed event faced by the 
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patient that involves or is alleged to include drug therapy that actually or potentially 
interferes with required health result (Cipolle, et al., 1998; 2004). At present, the terms 
usually defined as “an occasion or condition involving drug therapy that actually or 
potentially interferes with the desired health outcomes” (Pharmaceutical Care Network 
Europe, 2010). The definitions of drug related problems varies and depend on the 
general cultural factors especially the function of disease and choices of treatment for 
that disease in that society. It also depends on the language and the country’s underlying 
health system (Van Mil, et al., 2001). DRPs have developed to become a unique area of 
clinical pharmacy research.  
2.2 PREVALENCE OF DRP FROM OTHER STUDIES 
Roughead (2004) who reviewed 1000 clinical case notes acknowledged 99% of 
patients had slightest one medication-related problem. In their study, high number of 
patients were found to need additional monitoring, additional medication, were using 
the wrong or unsuitable medication and were using insufficient medication. 
Cardiovascular, nervous system, alimentary and respiratory drugs were accounted for 
69% of the drug-related problems (Roughead, 2004). Although the setting of both 
studies were different (one in community pharmacy and one in hospital), the authors 
agreed that prevalence of DRPs were high among patients. Some potential drug related 
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problems if over-looked can manifest and cause actual drug related problems 
(Roughead,2004)   
     According to Lewinski, et al. (2010) who surveyed patients in 69 community 
pharmacies in Berlin with a checklist for estimating quality assurance, among 3040 
surveyed patients, 638 (21.0%) patients who visited the pharmacies were detected 
having DRPs. His study also identified significant risk factors such as self-medication, 
therapeutic errors and information problems. Drug classes that associated with the 
DRPs detected were NSAIDs, antibiotics, nasal preparations and cough medications. 
2.3 RISK FACTORS OF DRPs 
Studies by Sarah (2000) showed inconsistent associations of DRPs were reported for 
race but more on type of lifestyle of that race personally. She did mention that the 
rationales for the rising prevalence of allergic diseases over the most recent decades in 
the world are indefinite. It was thought that the causes were originated among factors 
from the environment.  
There were differences in the occurrence of allergic diseases between rich and poor 
people, among urban and rural areas, and between Eastern and Western countries. But, 
according to Rajesh (2011) prevalence of allergy between races is significant. So there 
are two schools of thought for this issue.  
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Significant inter-individual variability was evident in allergy incidence. Studies by 
Shusterman (2003) proved that advancing age predicted a greater response to allergens 
(p <0.01). No gender effect was observed. There was correlation of DRP occurrences 
among certain diseases such as asthma and age.  
Published journal by McMillan, et al. (1986) stated that DRPs especially ADR are 
age linked especially among elderly individuals or those with poly-pharmacy. The 
knowledge of the comparative importance of various risk indicators would guide to 
better risk management strategy among different patient subgroups. This finding is in 
accordance to those reported from Denmark, (Hallas, et al., 1992) and the Netherlands 
(Veehof, et al., 1999). There were comparative risks in developing ADRs for female 
patients. However, there were several differences in patient characteristics between the 
surveys.  
Lewinski, et al. (2010) also did mention that age, gender and the quantity of dispensed 
medication had little control on occurrence of DRPs. The much larger sample sizes in 
the earlier studies allowed them to be more alert in detecting the association between 
female gender and the possibility of increasing ADRs. 
During his latest studies, Beers (1991) compared few studies about risk factors of 
DRP and summarized that there are contradiction between age and DRP but the actual 
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reason of DRP occurrence is poly-pharmacy. The incidence of DRP increases 
exponentially once and aged person takes more than five types of medications (Slater, 
1993). Other published studies indicate that other contributing factors to DRP such as 
medical conditions, type of medications, social situation, ability to pay for the treatment 
and medication and understanding the treatment regimen. There are recorded statistics 
showing that DRPs are also caused by these factors (Kaufman, 2002).  
Ghouri (2008) recorded that prevalence of allergic rhinitis with DRP have increased 
substantially in recent years. A similar increase in prescriptions for oral and topical 
antihistamines and drugs used in nasal allergy in patients with allergic rhinitis were also 
observed.  Whereas Thomson (2001) proved that prevalence of topical corticosteroid are 
quite high and differ among countries. It depends on the prescribing and dispensing 
practice in the particular country. Contact dermatitis has been recorded with the non-
fluorinated steroid (Thomson, 2001). Occurrences of DRPs would increase if the 
practice goes on without realization. Tibblea (1999) also recorded those antipyretics 
especially NSAIDs showed high prevalence which depended much on the prescribing 
and dispensing practice of the area. He also mentioned that the DRPs caused such as 
enteropathy was independent of the particular type or dose of NSAID being taken.  
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Thomas (1978) mentioned that oral and topical antibiotics caused bacterial resistance 
for frequent usage and telling that systematic comparisons of resistance prevalence in 
dissimilar parts of the world might assist to define optimal antibiotic usage practices.  
Lewinski (2010) study among patients who go to community pharmacies showed that of 
the 3040 surveyed patients, 638 (21.0%) were affected by DRPs. Risk factors identified 
were self-medication and new medication, especially new prescriptions. The two major 
groups of DRPs were therapeutic errors and information problems. He also proved that 
drug classes most frequently associated with DRPs were NSAIDs, antibiotics, nasal 
preparations and cough medications.  
Donna (2003) adapted Beers Criteria to enhance detection of unsuitable medication 
use among the elders. She made adjustments such as list of current medications, medical 
history specifications and mentioned that changes must be done occasionally because of 
improvements in prescribing and dispensing procedures from time to time.  
2.4 RECENT STUDIES AND FINDINGS ON THE TYPES OF  
             DRPs DETECTED BY COMMUNITY PHARMACISTS. 
Unsatisfactory outcomes of treatment can be detected by careful monitoring. Of all 
these causes, inappropriate monitoring may be the most important and should be 
appreciated by the pharmacy profession (Van Mil, et al., 2001).There are three main 
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processes where a drug-related problem can occur as described by him which is the 
prescribing processes, dispensing processes and drug use processes(Van Mil, et al., 
2001). 
Table 2.0 shows various findings from researches done on types of DRPs detected. 
Table 2.0 Findings on types of DRPs  
RESEARCHER FINDINGS ON TYPES OF DRPs  
 
Uday (2012) High pill burden reduces compliance with drug therapy. It also 
increases the possibility of adverse medication reactions.  
Cheung (2009) The research team identified that: poor, frequently untidy, 
handwriting; ‘traps’ (look-alike and sound-alike medications); lack 
of effective controls; and lack of concentration caused by 
interruptions were causes of DRPs. 
WHO (2008) 
 
Adverse effects of drugs (one DRP factor) have an extensively 
variable occurrence according to individual sensitivity such as 
nausea, dizziness, diarrhea, malaise, vomiting, headache, dermatitis 
and dry mouth. 
Paulino, et al. (2007)   Ambiguity or short of knowledge about the intention or function of 
the drug was a cause of DRP. 
Horne (2005)    Medication tolerance; a DRP is normally encountered when a 
patient's reaction to a particular drug and concentration of the drug 
is gradually reduced, requiring a raise in concentration to achieve 
the desired effect and cause non-compliance. 
Stagnitti (2004) The prescribers (pharmacists) can be influenced by external entities, 
such as the pharmaceutical industry, and may not prescribe the most  
appropriate medicine professionally which may cause DRP. 
Ukans (2004) DRPs due to misprescribing cost a lot of waste barely affordable by 
many people who pay for their own prescriptions  
Schioler (2001) Adverse effects a DRP factor could cause a reversible or irreversible 
transform, which include a raise or reduction in the vulnerability of 
the patient to other chemicals, foods, or treatments, such as 
medication or food interactions. 
Leape (2000) DRP errors originating from the interpretation of the prescription 
order forms were the second most frequent complaint from a list of 
90,000 complaints made to the American Medical Association over 
a period of seven years. 
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2.5 RECENT STUDIES ON METHODS TO DETECT DRPs BY  
             COMMUNITY PHARMACISTS. 
Community pharmacists have contributed to studies and medication reviews to reduce 
DRPs due to many factors. Table 2.1 shows methods created or developed by 
researchers to detect DRPs among patients in community pharmacies. 
Table 2.1 Methods to detect DRPs developed by community pharmacists 
RESEARCHER METHODS TO DETECT DRPs BY COMMUNITY 
PHARMACISTS 
Cheung (2009) Barcode technology is estimated to prevent about 13,000 
dispensing errors and 6,000 potential adverse drug events per 
year. Bar-code technology may have a positive impact on 
serious medication errors and deserves sturdy consideration as a 
tool to improve patient safety. 
Haynes (2008) Indicators are quantitative tools expressed as, rate, ratio, or  
percentage that evaluate actual performance, and compare it 
with a target or standard.  These indicators measure all serious 
events such as DRPs that require further analysis and 
investigation in an occurrence such as death due to medical 
error. 
Ostwald (2007) The implementation of a computerized drug–drug interaction 
alerting system in community pharmacies and physicians' 
offices proved that the dispensing of prescriptions with severe 
interactions by pharmacists was reduced. 
Zarowitz (2005) Survey among pharmacists performing drug therapy reviews 
and training their patients about medication safety and poly-
pharmacy, as well as collaborating with physicians and patients 
to correct poly-pharmacy problems. This survey led to a 
noticeable improvement in interactions and cost.  
In the last decade, risk factors for DRPs have been identified and many methods were 
used to various degrees to identify patients at risk. Reliable and valid tools to correlate 
these risk factors to actual or potential DRPs have been developed and may be useful in 
community pharmacies (European Allergy White Paper, 2004). A simple process to 
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identify patients at risk for DRPs would increase a pharmacist's efficiency in conducting 
comprehensive drug assessments in patients at highest risk. 
A study of southern Mexico was undertaken to analyze the scale of the inadequate 
drug advice provided, and to identify the contributing factors. The reasons for poor 
recommendation were identified as a lack of knowledge about regular treatments and 
authorized regulations, lack of skills among pharmacy staff and a malfunction to 
execute the existing regulations layering the drug sales and its retail practices. (Bernt, 
2000) 
In Sweden, the retail pharmacy system of community pharmacies and hospital 
pharmacies are grouped into one government-owned chain, recognized as Apoteket AB.  
A categorization system programme for reporting DRPs and pharmacy interventions 
was introduced in 1995 and included into the software programme of all community 
pharmacies in 2001. Patient medication profiles are kept in pharmacies nationwide, and 
a new national registered drugs list dispensed to patients became available in 2006. The 
coding system analyzes every section of the DRP management process; the type of 
problem, potential negative outcomes, pharmaceutical decisions and persons involved. 
Two-thirds of clinical DRPs needed a prescription alteration, the most common being 
an adjustment in dosage or drug regimen. (Dhalla, 2002) 
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In Japan, community pharmacists are currently facing a dilemma and developing 
strategies for dispensing mistakes, because there is growing public awareness on 
medical and medication events. To explain the connection between human mistakes 
measures and preventive measures for avoiding errors, questionnaire outcome was 
analyzed. This study was efficient for adopting competent preventive measures for 
medical and medication event and analyzing risk supervision in pharmacies (Anne, 
2008). 
In Britain, tools introduced by Helper and Strand facilitated self-directed learning 
about diseases and drugs, acquisition of relevant patient data, a consistent and stepwise 
approach to the identification and resolution of drug-related problems, documentation of 
care provided, and continuity of care (Adler, 2004). 
 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
 
Figure 2.0- Example of a plan of DRP detection (Hepler’s cycle) 
Drug utilization review (DUR) is a quality assurance system that holds promise as a 
tool that, if implemented effectively, could enhance appropriate drug use. Evaluation 
and management of public and private DUR systems links documentation of processes 
of care, such as pharmacists, cognitive service and patient interventions (Joel, 2007). 
Research to create consistent methods for measuring and monitoring the worth of 
community and clinical pharmacy services must be continued. Mechanisms must be 
developed to give confidence and reward pharmacists who without fail provide services 
to pharmaceutical care (Bjerum, 2003). 
 
1. Record and interpretation of patient 
information 
2. Record therapeutic strategies 
3. Review Therapeuticplan 
4.  Propose Monitoring plan 
5. Dispensing and counseling 
6.  Implementing the 
Monitoring Strategies 
7.  Recognizing problem/issues 
8.  Respond to the problem 
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2.6 DEVELOPMENT OF DRUG RELATED PROBLEM (DRP)  
             CHECKLISTAS A METHOD OF DRP DETECTION 
2.6.1 SEARCH RESULTS OF RECENT STUDIES ON DRP CHECKLIST OR 
DRP CLASSIFICATION DEVELOPMENT 
DRP classification or DRP checklist were introduced by researchers in pharmaceutical 
care to help health care professionals be more aware of patient care issues such as ADR 
or poly-pharmacy and to create a better understanding on standard medical and 
medication procedures. These checklist or classifications are based on evidence- based 
data from patients’ case notes or medical histories (Bob, 2009; Andrea, 2007) 
 Williams (2012) developed a system for classifying drug-related problems 
known as (DOCUMENT) in community pharmacy was developed by research. This 
DRP checklist which was validated in two pilot studies was then incorporated into a 
software programme to be used by 185 Australian pharmacies. The system helped the 
pharmacists with a useful and easy-to-use tool for recording DRPs and clinical 
interventions. 
 Vinks TH (2009) explored whether a community pharmacist involvement 
reduces the number of potential DRPs in elderly patients. This study proved noteworthy 
21 
 
influence of the community pharmacist in cutting down prevalence of potential DRPs 
among their elderly patients. 
Bob (2009) created an evidence-based checklist to identify potential drug related 
problems (PDRP) in patients with type 2 diabetes. With the guide of PCNE 
(Pharmaceutical Care Network Europe) classification, all the DRPs were detected and 
categorized. This was the first tool developed exclusively to distinguish potential DRPs 
in patients with type 2 diabetes.  
Andrea (2007) developed DRP checklist to assess DRP problem management 
process among their pharmacies. Using the checklist, they introduced coding system 
that could explain the management process for DRPs. Data concerning the entire 
process used to deal with drug-related problems can be helpful in improving medication 
safety, education, and mutual care. 
2.6.2 CONCLUSION OF RECENT STUDIES ON DRP CHECKLIST OR 
CLASSIFICATION DEVELOPMENT 
The above studies which were done recently are examples of drug related problem 
checklist or classification development in other countries. These countries proved that 
the DRP checklist or classification is one useful method to survey drug related problems 
in a chosen setting, area, population or confirmation of the definition of DRPs in the 
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selected area. It could be adapted to fit the inclusion and exclusion criteria in a hospital 
or community pharmacies. From those studies, the checklists were able to calculate 
prevalence and types of DRPs.  The data that was collected were useful to the healthcare 
providers to provide a good pharmaceutical care plan where cost and clinical 
interventions played a major role in the decision making in a treatment plan.  
Drug related problems issues were also surveyed in our country (Elkelmi, 2011; 
Chua, 2012) but these survey methods did not include the development of a DRP 
checklist for community pharmacists. 
2.7 AIM OF DRP CLASSIFICATION 
Every health system needs DRP classification to document drug related problems 
encountered in daily pharmacy practice including community pharmacies in their 
country. Classification system enables documentation of DRP information when 
providing pharmaceutical care (including causes of DRP). Interventions will be 
documented systematically for further references. DRP classification also enables 
research of prevalence and incidence of DRPs (PCNE 2010).  
There are many classifications available to code drug related problems but not all 
those classifications are easy to use. Van Mil, et al., (2004) published an overview of 
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such classifications. He mentioned that a practical classification should at least have the 
following characteristics: 
a) Suitable for both scientific studies and use in the pharmacy. 
b) Easy to use in daily routine. 
c) Minimally consisting of three parts: problem, intervention, and the degree to   
which the problem could be solved. 
d) Structured like a decision tree (main groups and sub-groups) supporting   
computer aided use.  
e) Open structure enabling introduction of additional coding levels without   
changing the basic structure. 
f) Problems defined should be clear and lead to one choice of coding only. 
g) Focus on the problem itself not on its cause or consequence.  
h) Suitable for the documentation needed for the remuneration of cognitive  
services. 
 
 
 
24 
 
Figure 3.0 is a summary of a few DRP classification systems created by other countries 
or healthcare settings and their differences in classification categories, causes, validation 
status and availability of intervention classification. PCNE V6.1 proved to be the most 
eligible and accepted by most developed countries as a standard guide for DRP 
detection. Other classifications had hierarchical problems, many DRP categories and 
most of them were not validated. So, many users had difficulties and spent more time on 
classifications. 
System Categories 
Hierarchical  
problem 
classification* 
Causes 
separated* 
Validated* 
Intervention 
classification* 
Cipolle et al 7 N N N Y 
Hepler/Strand 8 N N N N 
PCNE V6.1 6 Y Y Y Y 
PIE-system 6 N Y ± Y 
Westerlund 13 N I ± Y 
* N=No, I=Integrated, Y=Yes, ± Not fully 
Figure 3.0 Examples of available DRP classifications with their comparisons 
These DRP classifications shown in Figure 3.0 have been developed or adapted 
according to their countries/district health system. But these systems have different 
